Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melapuldencel-T
- Development stage
- Discontinued
- Lead developer
- Lisata Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Melapuldencel-T is an autologous cellular immunotherapy developed for the treatment of metastatic melanoma. The therapy consists of a patient's own dendritic cells that have been loaded with antigens from irradiated autologous melanoma-initiating (stem) cells. This personalized approach aims to train the patient's immune system to recognize and destroy cancer stem cells, which are believed to be responsible for tumor recurrence and metastasis. The product is typically administered alongside granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance the maturation and activity of the dendritic cells. While it showed promise in Phase 2 trials and entered a Phase 3 trial (the "Intus" study), development was suspended by the developer (then Caladrius Biosciences) due to strategic and financial considerations.
- Other names
- Autologous Dendritic Cell-Tumor Cell ImmunotherapyDC-TC
02
Targets
γδ TCR (T-cell receptor)MAA-MHC-I (Melanoma-associated antigens presented on MHC class I)
Beyond the preview
Go deeper on melapuldencel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melapuldencel-T.